Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Vertex Pharmaceuticals Inc. pages available for free this week:
- Income Statement
- Balance Sheet: Assets
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Liquidity Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Price to FCFE (P/FCFE)
- Operating Profit Margin since 2005
- Return on Assets (ROA) since 2005
- Total Asset Turnover since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Vertex Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
- Debt Ratios Including Operating Lease Liability
- The debt to equity ratio including operating lease liability shows a relatively stable trend from the end of 2020 through 2023, consistently ranging from 0.04 down to 0.02, indicating a low level of financial leverage through debt within the company’s capital structure during this period. However, starting in late 2024 and through mid-2025, the ratio shows a marked increase, reaching as high as 0.1 before stabilizing slightly lower around 0.09. A similar pattern is observed in both the debt to capital and debt to assets ratios including operating lease liability, which also remain low and stable initially before increasing substantially in late 2024 and 2025. This suggests a recent increase in the company's reliance on debt and lease liabilities in its capital structure.
- Financial Leverage
- Financial leverage remains relatively consistent, hovering between 1.28 and 1.4 across the entire timeline. Minor fluctuations are present, but overall the company maintains a low to moderate use of debt relative to equity. There is a slight uptick in financial leverage towards the end of the dataset in late 2024 and early 2025, which aligns with the observed increases in debt-related ratios during the same period.
- Interest Coverage Ratio
- The interest coverage ratio, starting from the first data points in early 2021, exhibits an overall increasing trend through 2023 and into early 2024, rising from around 54.6 to a peak exceeding 111.6. This indicates a strengthening ability to cover interest expenses from earnings. However, there is a notable sharp decline at the end of 2024, dropping precipitously to negative values (-11.94), which suggests a period of negative earnings or impaired ability to cover interest costs. Subsequently, the ratio rebounds dramatically to very high values by mid-2025 (258.29), implying either a significant recovery in earnings or a reduction in interest expense. This high volatility in interest coverage towards the end of the period signals a potential short-term financial stress followed by rapid improvement.
- Overall Financial Position and Risk Assessment
- The company maintains conservative financial leverage with minimal debt over the majority of the analyzed periods, as reflected by the low debt ratios under 0.05. The increase in debt-related ratios in 2024, along with fluctuations in financial leverage and the large swings in interest coverage ratio, could indicate a strategic shift or an unusual event affecting the company's earnings and debt levels. This could raise concerns regarding short-term liquidity or earnings volatility, although the return to strong interest coverage suggests potential resilience or management actions to address the transient financial challenges.
Debt Ratios
Coverage Ratios
Debt to Equity
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||||||
Total debt | |||||||||||||||||||||||||||||
Shareholders’ equity | |||||||||||||||||||||||||||||
Solvency Ratio | |||||||||||||||||||||||||||||
Debt to equity1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Debt to Equity, Competitors2 | |||||||||||||||||||||||||||||
AbbVie Inc. | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Merck & Co. Inc. | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Debt to equity = Total debt ÷ Shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
- Shareholders’ Equity
- The shareholders’ equity shows a clear upward trend from March 31, 2020, through June 30, 2025, with some fluctuations observed after March 31, 2024. Initially, equity grew steadily from approximately 6.46 billion USD in March 2020 to about 17.58 billion USD by the end of December 2023. This represents a strong expansion over the nearly four-year period. The equity values peaked notably in December 2023 at 17.58 billion USD before declining to approximately 14.77 billion USD by June 2024. A recovery trend follows, with equity increasing again to reach around 17.17 billion USD by June 2025. This suggests some volatility in the more recent quarters but an overall positive growth trajectory across the entire timeframe.
- Total Debt and Debt to Equity Ratio
- There is no data available for total debt and debt to equity ratio for any of the periods in the dataset. As a result, it is not possible to analyze the company’s leverage position or assess financial risk related to debt.
Debt to Equity (including Operating Lease Liability)
Vertex Pharmaceuticals Inc., debt to equity (including operating lease liability) calculation (quarterly data)
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Debt to equity (including operating lease liability) = Total debt (including operating lease liability) ÷ Shareholders’ equity
= ÷ =
The financial data reveals distinct trends in both debt levels and shareholders’ equity over the observed periods. There is a clear trajectory of increasing total debt from the first recorded value in March 2021 through December 2024, albeit with fluctuations towards the latter quarters.
- Total Debt (including operating lease liability)
- The total debt starts at approximately $350 million in March 2021 and gradually increases with minor variations, peaking sharply to nearly $1.59 billion by June 2025 before slightly decreasing in subsequent quarters. This represents a significant rise in debt levels, especially notable from December 2024 onwards.
- Shareholders’ Equity
- Shareholders’ equity shows a consistent upward trend from March 2020 through December 2023, increasing from about $6.46 billion to $17.58 billion. However, a decline is observed starting in March 2024, with the equity falling to approximately $14.77 billion by June 2024, before recovering gradually to around $17.18 billion by June 2025. This pattern suggests a period of decreased equity followed by partial restoration.
- Debt to Equity Ratio
- The debt to equity ratio remains low and stable, fluctuating between 0.02 and 0.04 from March 2021 through December 2023, indicative of prudent leverage relative to equity. A notable increase emerges starting in March 2024, rising sharply to 0.10 by June 2024 and stabilizing near 0.09 thereafter. This change reflects the surge in total debt relative to shareholders’ equity observed in the same periods.
Overall, the data indicate that while the company maintained strong equity growth and low leverage ratios for several years, there was a marked shift in 2024 characterized by a rapid increase in debt and a temporary dip in equity. This has led to a higher debt to equity ratio, signifying increased financial leverage. The reasons behind these changes are not provided, but the implications could include increased financial risk and altered capital structure strategy during that timeframe.
Debt to Capital
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||||||
Total debt | |||||||||||||||||||||||||||||
Shareholders’ equity | |||||||||||||||||||||||||||||
Total capital | |||||||||||||||||||||||||||||
Solvency Ratio | |||||||||||||||||||||||||||||
Debt to capital1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Debt to Capital, Competitors2 | |||||||||||||||||||||||||||||
AbbVie Inc. | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Merck & Co. Inc. | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
The financial data under review indicates fluctuations and trends primarily observable in the total capital figures over the reported periods. There is a noticeable absence of data regarding total debt and the debt to capital ratio, which limits the scope of leverage analysis.
- Total Capital
- The total capital shows a consistent upward trend from March 31, 2020, through December 31, 2023. Starting at approximately US$6.46 billion in March 2020, the value increases steadily quarter over quarter, reaching a peak of about US$17.58 billion by December 31, 2023. This growth reflects ongoing capital accumulation or investment activities over this timeframe.
- Beginning in March 2024, a decline appears in total capital, dropping from US$18.55 billion in March 2024 to US$14.77 billion by June 30, 2024. Following this decline, the capital level partially recovers toward the end of the reporting period, reaching approximately US$17.18 billion by June 30, 2025. This pattern may indicate significant capital divestitures, adjustments, or extraordinary financial events affecting capital structure in early 2024 followed by stabilization.
The absence of data for total debt and the debt to capital ratio means there is no available information to assess the financial leverage or solvency position during these periods. This omission restricts the evaluation of the company’s risk profile in terms of debt financing.
Overall, the capital base has generally been expanding with a notable contraction in early 2024, followed by partial recovery. Without complementary debt data, conclusions about capital structure efficiency, debt management, or funding strategy remain limited.
Debt to Capital (including Operating Lease Liability)
Vertex Pharmaceuticals Inc., debt to capital (including operating lease liability) calculation (quarterly data)
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Debt to capital (including operating lease liability) = Total debt (including operating lease liability) ÷ Total capital (including operating lease liability)
= ÷ =
- Total Debt (including operating lease liability)
- The total debt levels appear first from March 31, 2021, showing an initial value of approximately 350 million USD. Over the next few quarters until March 31, 2024, the debt remains relatively stable, fluctuating slightly between 348 million USD and 382 million USD, indicating controlled or stable borrowing. However, starting June 30, 2024, there is a marked increase in debt, jumping sharply to around 587 million USD and remaining significantly elevated in subsequent quarters, exceeding 1.5 billion USD in the middle quarters of 2025 before slightly decreasing by June 30, 2025. This suggests a recent substantial increase in leverage or borrowing during this period.
- Total Capital (including operating lease liability)
- Total capital shows a consistent upward trend across all observed periods, rising from approximately 6.46 billion USD in March 31, 2020, to over 18.7 billion USD by June 30, 2025. This growth reflects an overall expansion in the company’s capital base, possibly driven by equity issuance, retained earnings growth, or revaluation adjustments. Despite some fluctuations, the capital base remains broadly stable and growing over time with no significant contractions.
- Debt to Capital Ratio (including operating lease liability)
- The debt-to-capital ratio is low and stable in early periods, ranging from 0.02 to 0.04 from March 31, 2021, through March 31, 2024, indicating a conservative capital structure with low leverage. However, this ratio increases significantly starting June 30, 2024, reaching approximately 0.09 and sustaining this higher leverage level through June 30, 2025. This ratio change corresponds directly with the increase in total debt and suggests a shift toward higher financial leverage during this later period.
- Overall Insights
- The data reveals a consistent growth in total capital over the observed timeframe, signaling business growth or capital infusion. The low and stable debt levels and debt-to-capital ratios until early 2024 illustrate a cautious financial approach with minimal reliance on debt. The sharp increase in both total debt and leverage ratio in mid-2024 and beyond indicates a strategic shift towards increased debt financing. This may reflect new investment initiatives, acquisitions, or other capital-intensive activities. Continuous monitoring of this increased leverage will be important to assess its impact on financial risk and cost of capital.
Debt to Assets
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||||||
Total debt | |||||||||||||||||||||||||||||
Total assets | |||||||||||||||||||||||||||||
Solvency Ratio | |||||||||||||||||||||||||||||
Debt to assets1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Debt to Assets, Competitors2 | |||||||||||||||||||||||||||||
AbbVie Inc. | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Merck & Co. Inc. | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The analysis of the available quarterly financial data reveals a consistent upward trend in total assets over the observed period. Beginning at approximately 8.89 billion US dollars as of March 31, 2020, the total assets steadily increased each quarter, reaching around 24.04 billion US dollars by June 30, 2025.
This persistent growth in total assets indicates expansion or accumulation of resources and investments. However, the absence of data for total debt and debt-to-assets ratio limits the ability to assess the company's leverage or debt management during this timeframe.
Key observations include:
- Growth Trajectory
- Total assets have shown robust growth across all quarters, with no recorded declines or fluctuations, signifying sustained asset accumulation or appreciation.
- Quarterly Consistency
- The increase in total assets appears relatively smooth without abrupt changes, suggesting controlled and steady financial management or investment activities.
- Data Gaps
- Due to missing information on total debt and debt to assets ratio, it is not possible to evaluate the company's capital structure, leverage risks, or solvency trends comprehensively.
In summary, the data available reflects positive asset growth, but an incomplete financial picture warrants caution in drawing conclusions about overall financial health or risk profiles.
Debt to Assets (including Operating Lease Liability)
Vertex Pharmaceuticals Inc., debt to assets (including operating lease liability) calculation (quarterly data)
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Debt to assets (including operating lease liability) = Total debt (including operating lease liability) ÷ Total assets
= ÷ =
- Total Debt (including operating lease liability)
- The total debt figures begin to appear starting from the first quarter of 2021, with an initial amount of approximately $350 million. Through 2021 and 2022, the debt remains relatively stable, fluctuating modestly in the range of about $354 million to $382 million. However, from 2023 onward, there is a slight downward trend through most quarters, reaching a low near $348 million towards mid-2024. Notably, there is a sharp and substantial increase in the debt level in the third quarter of 2024, surging to over $1.5 billion, and this elevated debt level persists through the subsequent periods until mid-2025.
- Total Assets
- Total assets show a consistent upward trend across all presented periods. Starting from about $8.9 billion in the first quarter of 2020, asset values increase steadily each quarter, surpassing $18 billion by the end of 2022. The upward trajectory continues through 2023, reaching over $22 billion by early 2024. Although there is a notable drop in total assets during mid-2024, falling to approximately $20.1 billion, the asset base recovers quickly, resuming growth to exceed $24 billion by mid-2025. Overall, this indicates expanding asset holdings with only a brief period of contraction in 2024.
- Debt to Assets Ratio (including operating lease liability)
- The debt to assets ratio starts being reported in early 2021 at approximately 3%. The ratio remains stable through 2021 and 2022, fluctuating between 2% and 3%, reflecting the relatively low leverage given the high asset base. In 2023 and early 2024, the ratio stays around 2%. However, from the third quarter of 2024, coinciding with the sharp increase in total debt, the ratio escalates significantly, tripling to around 7%. This elevated leverage level is sustained through mid-2025, indicating a notable shift in the company's capital structure with increased reliance on debt relative to assets during this period.
- Summary of Trends and Insights
- Over the examined quarters, the company demonstrates steady asset growth and controlled debt levels for most of the period, maintaining a low debt-to-asset ratio. The notable event in late 2024, a sizeable increase in total debt and corresponding spike in leverage, suggests a strategic change in financing or capital allocation, possibly involving significant borrowing or liabilities taken on. Despite this increased leverage, total assets remain robust, recovering after a brief dip in mid-2024. This pattern may indicate financing activities related to investments, acquisitions, or other financial restructuring measures. Overall, the financial position reflects a historically conservative leverage profile until late 2024, when a marked change in debt management occurs.
Financial Leverage
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||||||
Total assets | |||||||||||||||||||||||||||||
Shareholders’ equity | |||||||||||||||||||||||||||||
Solvency Ratio | |||||||||||||||||||||||||||||
Financial leverage1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Financial Leverage, Competitors2 | |||||||||||||||||||||||||||||
AbbVie Inc. | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Merck & Co. Inc. | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Financial leverage = Total assets ÷ Shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
- Total Assets
- The total assets demonstrate a consistent upward trend from March 31, 2020, through June 30, 2025. Starting at approximately $8.9 billion, total assets increased steadily quarter over quarter, peaking near $23.9 billion by March 31, 2025. There are no notable declines or interruptions in this growth trajectory, indicating a sustained expansion in the company's asset base over the period.
- Shareholders’ Equity
- Shareholders’ equity also follows a positive trend, rising from about $6.5 billion in March 2020 to roughly $17.2 billion in June 2025. This increase is relatively steady, although there is a slight deceleration in growth in the periods corresponding to late 2023 and early 2024 where values plateau somewhat before resuming growth. The progression of equity appears to be in line with the growth in total assets.
- Financial Leverage
- Financial leverage ratios fluctuate within a narrow band throughout the analyzed periods. The ratio begins at 1.38 in March 2020 and exhibits minor variation, moving between a low of approximately 1.28 and a high of 1.42. Notably, there is a modest decline in leverage from mid-2020 through early 2023, indicating a slight reduction in the relative amount of debt financing compared to equity. However, starting mid-2023, the leverage ratio shows a tendency to increase again, reaching levels above 1.4 by mid-2025. This suggests a cautious but growing reliance on financial leverage in recent periods.
- Overall Trends and Insights
- The company exhibits continuous asset growth accompanied by increasing shareholders’ equity, reflecting positive capital accumulation and retained earnings or additional equity infusion. Financial leverage remains relatively stable with minor fluctuations, indicating prudent financial management with moderate reliance on debt. The recent uptick in leverage ratios signals a potential strategic shift towards leveraging capital structure more aggressively. The balance between asset growth and equity increase, alongside manageable financial leverage, suggests a stable financial position with controlled risk exposure over the observed timeframe.
Interest Coverage
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||||||
Net income (loss) | |||||||||||||||||||||||||||||
Add: Income tax expense | |||||||||||||||||||||||||||||
Add: Interest expense | |||||||||||||||||||||||||||||
Earnings before interest and tax (EBIT) | |||||||||||||||||||||||||||||
Solvency Ratio | |||||||||||||||||||||||||||||
Interest coverage1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Interest Coverage, Competitors2 | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Interest coverage
= (EBITQ2 2025
+ EBITQ1 2025
+ EBITQ4 2024
+ EBITQ3 2024)
÷ (Interest expenseQ2 2025
+ Interest expenseQ1 2025
+ Interest expenseQ4 2024
+ Interest expenseQ3 2024)
= ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Earnings before interest and tax (EBIT)
- The EBIT figures exhibit fluctuations across the periods analyzed. There was a general upward trend from March 2020 through December 2020, peaking at approximately 904,911 thousand USD. In 2021, the EBIT showed volatility with a negative value of -28,777 thousand USD in June, followed by a recovery and another strong performance peaking at over 1,099,996 thousand USD in September 2021. Throughout 2022 and early 2023, EBIT remained robust, maintaining values consistently over 900,000 thousand USD and reaching 1,182,000 thousand USD in December 2023. However, a significant decline appears in June 2024 with EBIT dropping dramatically to -3,381,300 thousand USD, indicating a potential one-off or extraordinary event. Subsequently, EBIT rebounded sharply and stabilized above 700,000 thousand USD in the final quarters observed.
- Interest expense
- Interest expense shows a gradual but steady decline over the entire timeline. Starting at approximately 14,136 thousand USD in the first quarter of 2020, it declines slowly to around 7,500 thousand USD by the end of 2024. The reduction continues further into mid-2025, reaching values as low as 2,800 thousand USD in March 2025 and slightly increasing thereafter. This pattern suggests effective management of debt-related costs or a reduction in debt levels over time.
- Interest coverage ratio
- The interest coverage ratio improves markedly over the period, indicating stronger ability to cover interest expenses with EBIT. From values in the mid-40s in mid-2020, the ratio rises steadily, exceeding 100 by late 2023. The substantial dip to 6.14 in March 2024 aligns with the significant drop in EBIT during the same quarter, highlighting a temporary strain on financial coverage capacity. After this, the ratio recovers impressively, reaching a peak of 258.29 by June 2025. This pattern reflects strong operational earnings performance relative to interest expenses, aside from the identified anomaly in mid-2024.